The Technical Advisory Group (TAG) of the World Health Organization (WHO), has recommended emergency use listing (EUL) status for Covaxin, a covid-19 vaccine developed by Bharat Biotech.
WHO is in the process of evaluating Covaxin’s clinical trial data for use of EUL. The TAG on October 26 had sought “additional clarifications” from the company for Covaxin to conduct a final “risk-benefit assessment” for EUL of the vaccine.
The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a Covid-19 vaccine can be listed for emergency use under the EUL procedure.
Covaxin has demonstrated 77.8% effectiveness against symptomatic Covid-19 and 65.2% protection against the new Delta variant.
Bharat Biotech’s Covaxin and AstraZeneca and Oxford University’s Covishield are the two widely used vaccines in India.
Download Money9 App for the latest updates on Personal Finance.
Government’s 4th advance estimates for the crop year 2021-22
Updated: August 19, 2022FII buying impact on stock market; here are FII buying stocks list 2022
Updated: August 17, 2022Understand the link between crypto exchanges and money laundering
Updated: August 15, 2022Why mutual fund investment is falling ever since FIIs have made a comeback?
Updated: August 12, 2022Tariff increase on cards; 5g tariff plans in India to make data expensive
Updated: August 11, 2022Why wheat prices won’t fall even if wheat import duty is reduced?
Updated: August 10, 2022Know Nifty 50 forecast, Sensex 30 forecast
Updated: August 9, 2022